UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 9, 2005

PRO-PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Nevada	000-32877	04-3562325
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

189 Wells Avenue, Newton, Massachusetts	02459
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (617) 559-0033

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On May 9, 2005, Pro-Pharmaceuticals, Inc. issued a news release announcing the dosing of patients in a Phase II trial of its DAVANAT(R)/5-FU product has commenced. The Phase II clinical trial is in metastatic colorectal cancer patients who have disease progression after receiving standard chemotherapeutic regimens. A copy of Pro-Pharmaceutical's news release is attached as Exhibit 99.1 hereto and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits
99.1 News release of Pro-Pharmaceuticals, Inc. dated May 9, 2005.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

PRO-PHARMACEUTICALS, INC.

By: /s/ Carl Lueders

Carl Lueders
Chief Financial Officer

Date: May 18, 2005

Pro-Pharmaceuticals Announces Dosing of Cancer Patient with DAVANAT/5-FU in a Phase II Clinical Trial at Medical Oncology & Hematology, P.C.

NEWTON, Mass.--(BUSINESS WIRE)--May 9, 2005--Pro-Pharmaceuticals, Inc. (Amex: PRW), a developer of novel carbohydrate compounds that enable the targeted delivery of chemotherapy drugs to cancer cells, today announced the dosing of a colorectal cancer patient in a Phase II trial of its DAVANAT(R)/5-FU product candidate at Medical Oncology & Hematology, P.C. in Waterbury, Connecticut. The Phase II clinical trial is in metastatic colorectal cancer patients who have disease progression after receiving standard chemotherapeutic regimens.

Commenting on the announcement, Eliezer Zomer, Ph.D., Executive Vice President of Product Development, Pro-Pharmaceuticals said: "We welcome Dr. Kert D. Sabbath and his staff at Medical Oncology & Hematology, who have joined our Phase II clinical trial, as we continue to make solid progress in advancing our lead product candidate DAVANAT(R) through the clinical assessment program."

Phase ll Clinical Trial

The Company initiated a Phase II, multi-center, open-label trial to evaluate the efficacy and safety of intravenous DAVANAT(R) in combination with 5-Fluorouracil (5-FU) when administered in monthly cycles as third-, or fourth-line therapy for metastatic colorectal cancer. Seven medical centers will take part in this trial, which expects to enroll up to 38 patients and uses Simon's 2-stage design.

About DAVANAT(R)

DAVANAT(R) is a proprietary polysaccharide in a CARBOSOME(TM) formulation that enables the targeted delivery of chemotherapy drugs to protein receptors (lectins) that are unique to cancer cells.

Pro-Pharmaceuticals, Inc. - Advancing Drugs Through Glycoscience(R)

Pro-Pharmaceuticals is a drug development company commercializing a new generation of anti-cancer treatments using carbohydrate compounds to Glyco-Upgrade(TM) the safety and efficacy of FDA-approved chemotherapy drugs. The Company has been conducting pre-clinical studies for irinotecan, doxorubicin, oxaliplatin, paclitaxel, cisplatin, and most recently with bevacizumab both in combination with DAVANAT(R) and other polysaccharide compounds. Human colon and breast xenography are being used to optimize formulations and results show that DAVANAT(R) exhibits a broad spectrum of activity with tested drugs. Additional information is available at www.pro-pharmaceuticals.com.

FORWARD LOOKING STATEMENTS: Any statements in this news release about future expectations, plans and prospects for the Company, including without limitation statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements as defined in the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Because of uncertainties and risks facing the Company, many of which are outside of the Company's control, future events could cause actual results to differ materially from those indicated by such statements. More information about those risks and uncertainties is contained and discussed in the "Management Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors" sections of the Company's most recent quarterly or annual report and in the Company's other reports filed with the Securities and Exchange Commission. The forward-looking statements herein represent the Company's views as of the date of this press release and should not be relied upon to represent the Company's views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company's views to change, the Company disclaims any obligation to update such forward-looking statements.

CONTACT: Pro-Pharmaceuticals, Inc.
Anthony D. Squeglia, 617-559-0033
squeglia@pro-pharmaceuticals.com